# Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation

- Link: https://www.thailand-business-news.com/pr-news/nona-biosciences-appoints-dr-josh-xiao-as-chief-scientific-officer-to-advance-global-scientific-strategy-and-innovation
- Published: 2026-05-07T10:29:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ — Nona Biosciences ("Nona" or the "Company"),
a global biotechnology company advancing biotherapeutic discovery through innovative
technology platforms, today announced the appointment of Dr. Josh Xiao as Chief 
Scientific Officer (CSO). Dr. Xiao will be based in both US and China and report
directly to Dr. Di Hong, Chief Executive Officer of Nona Biosciences.

In this role, Dr. Xiao will lead the development of Nona’s global scientific strategy
and oversee the continued evolution of its technology platforms, especially Hu-mAtrIx
^(TM), the AI-driven drug discovery platform, with the goal of strengthening the
company’s long-term competitive advantage through integrated technological capabilities
and ecosystem collaboration. He will also guide the direction of scientific innovation
and support the advancement of novel therapeutic approaches across multiple disease
areas. In addition, Dr. Xiao will provide leadership to Nona’s global Project Leaders(
PLs), establishing a structured and scalable capability development framework to
enhance project execution, deepen scientific insight into partner needs, and enable
efficient integration of platform resources.

Dr. Xiao brings more than 25 years of experience in drug discovery and leadership
across both large biopharmaceutical companies and emerging biotechnology start-ups.
He earned his Ph.D. in Biochemistry from Louisiana State University and did his 
postdoctoral training at Columbia University. Most recently Dr. Xiao served as an
entrepreneur in residence at RA Ventures, the healthcare incubator of RA Capital
and co-founder of Starfish Medicines. Prior to that, he held scientific team leadership
roles at Amgen, Tularik (acquired by Amgen), and Millennium Pharmaceuticals (acquired
by Takeda), and led drug discovery function at several start-ups. His expertise 
spans target discovery and validation, antibody discovery and engineering, translational
medicines, and IND filing.

Dr. Di Hong, Chief Executive Officer of Nona Biosciences, commented: "We are very
pleased to welcome Josh to Nona at a pivotal stage in our growth. His extensive 
experience in drug discovery and translational medicines, as well as his strong 
track record in building high-performing scientific teams will be instrumental as
we continue to enhance our platform capabilities and global scientific leadership.
We believe he will further strengthen our ability to deliver high-quality innovation
and create long-term value for our partners."

"Nona Biosciences has been a leader in discovery and development of fully human 
antibodies and multi-specifics with its proprietary H2L2 Harbour Mice^(®) platform,
HCAb Harbour Mice^(®) platform, and Hu-mAtrIx^(TM) AI-driven drug discovery platform,
enabling several new ‘antibody+’ therapeutics modalities," said Dr. Josh Xiao, Chief
Scientific Officer of Nona Biosciences. "I am thrilled to join the Nona Biosciences
team, and very excited to help strengthen and expand our technology platforms to
help our partners succeed."

**About Nona Biosciences**

Nona Biosciences is a global biotechnology company committed to advancing biotherapeutic
innovation through cutting-edge technology platforms and integrated solutions. Nona
supports programs with its I to I^(®) framework, from early-stage ideas through 
preclinical research and advancement toward IND and early clinic, spanning target
validation and antibody discovery to early development.

Nona’s proprietary Harbour Mice^(®) technology platform generates fully human monoclonal
antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-
only (HCAb) format. The HCAb Harbour Mice^(®) is the world’s first fully human HCAb
transgenic mouse with clinical validation. This unique platform offers exceptional
versatility for diverse applications using fully human VH single-domain antibodies
as a plug-and-play system, including bispecific antibodies, multi-specific antibodies,
CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.

By integrating Harbour Mice^(®), single-B cell screening technology, NonaCarFx^(
TM) (a direct CAR-function-based screening platform), Hu-mAtrIx^(TM) (an AI-driven
drug discovery platform), Modalities-on-Demand^(®) (a next-generation modalities
solution), and end-to-end preclinical drug development services, Nona Biosciences
is dedicated to driving the global invention of transformative next-generation drugs.
For more information, please visit: [www.nonabio.com](https://www.nonabio.com).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation ](http://www.prnasia.com/story/archive/4953702_CN53702_0?rand=184833)
